BioEconomy: Significance, Challenges & Initiatives

NITI Aayog launched the “Roadmap for Building India as a Leading Bioeconomy Powerhouse by 2035” to scale the country’s bioeconomy to $2.6 trillion by 2047.

India’s Current Bioeconomy Landscape

Valuation: India’s bioeconomy expanded 16-fold over a decade, reaching $195.3 billion in 2025 and accounting for 4.8% of national GDP.
Segment: The bio-industrial segment is the largest contributor at 47%, followed by biopharmaceuticals, bio-services, and bio-agriculture.
Manufacturing Base: India operates over 700 USFDA-approved manufacturing plants, the most outside the USA, and remains the world’s largest vaccine manufacturer.
Global Standing: India ranks 12^th globally in biotechnology, 3^rd in Asia-Pacific, and climbed to 10^th in the 2025 Cytiva Global Biopharma Index.
Growth Targets: The government aims to scale the bioeconomy to $392 billion by 2030. NITI Aayog forecasts that it will reach $691 billion by 2035, positioning India as one of the top three biotech nations.

Significance of the BioEconomy for India

Export Window: The patent expiry of $300 billion in blockbuster biologics by 2030 opens a window where capturing a 2% share can earn India ₹6,400 crore annually.
Discovery Speed: Integrating artificial intelligence into discovery pipelines shortens clinical development timelines by 60-80%, accelerating the deployment of affordable biologicals.
Output Ratio: Every 1 percentage-point increase in national ethanol blending results in approximately ₹3,000 crore in foreign exchange savings.
Genomic Base: Expanding the GenomeIndia reference database to 100,000 individuals provides the population-scale genomic architecture required for affordable indigenous gene therapies.
Workforce Scale: The projected rise to 30 million high-value jobs by 2035 represents a ninefold increase on the current 3.3 million, helping absorb India’s working-age population.
Waste Conversion: Converting 600 million tonnes of agricultural residue into bioplastics and biofuels drives green growth towards the net-zero-by-2070 target.

Challenges with Bioeconomy in India

Approval Delay: Overlapping central approvals and state-level environmental clearances prolong regulatory timelines to an average of 900 days, compared with 500 days in peer nations.
Funding Gap: A severe funding gap across Series A and Series B creates a commercialisation “valley of death” that traps deep-tech ventures at the proof-of-concept stage.
Talent Deficit: A low density of 259 biotech researchers per million, coupled with only 25.6% STEM higher-education enrolment, restricts the advanced human capital the sector requires.
Import Reliance: Deep reliance on imported technologies (notably Chinese biocatalytic enzymes, CRISPR kits, and bioprocessing reagents) undermines supply-chain autonomy and increases production costs.
Data Isolation: Fragmented genomic, clinical, and hospital registries hinder the training of predictive AI diagnostic engines and the development of localised precision therapies.
Patent Obstruction: Ambiguity in the Patents Act regarding imported and genetically modified microbes discourages venture capital investment and technology translation.

Government Initiatives for Bioeconomy

Biomanufacturing Push: BioE3 Policy funds biofoundries and computational AI hubs to transition the economy towards high-performance biomanufacturing.
Population Sequencing: Genome India Project sequences whole genomes at population scale across diverse communities to build a national reference dataset for precision healthcare.
Biologics Scale-Up: Biopharma SHAKTI deploys institutional infrastructure and a 1,000-site clinical trial network to scale up affordable domestic manufacturing of advanced biologics.
Output Incentive: PLI Scheme for Pharmaceuticals provides output-linked financial incentives to expand domestic manufacturing of complex bulk drugs and biosimilars.
Academia Bridge: BIRAC deploys strategic funding, operational mentoring, and incubation infrastructure to bridge academic research and commercial biotechnology start-ups.
Translational Finance: National Biopharma Mission co-finances translational pipelines and shared technology platforms to accelerate the development of affordable, indigenous medical devices and vaccines.

Key Recommendations by NITI Aayog

Financial Catalysation: Establish a ₹50,000 crore BioEconomy Growth Fund under the ANRF or the RDI framework to deploy blended finance and viability gap funding for mid-to-late-stage ventures.
Regulatory Sandbox: Launch a time-bound, differentiated approval pathway with predefined milestone timelines for frontier modalities such as cell therapies, synthetic biology, and AI-designed drugs.
Robotic Biofoundries: Scale the national network of automated Design-Build-Test-Learn (DBTL) innovation hubs to accelerate prototyping in metabolic engineering without IP restrictions.
National BioMissions: Consolidate fragmented departmental programmes into six mission-mode flagship platforms, including GeneIndia and AgriBio 2.0, underpinned by ten-year execution roadmaps.
Cross-Sectoral Governance: Create inter-ministerial bodies, such as the National BioData Council and the Empowered Committee, to harmonise data standards and coordinate national asset tracking.
Talent Restructuring: Expand internationally benchmarked research fellowships and dedicated postdoctoral entrepreneurship pipelines to widen the expert human capital base.

“Biology is the technology of the 21st century.“ By building “BioViksit Bharat,” India can transform its demographic dividend into a bioeconomy dividend through innovation, sustainability, and inclusive biomanufacturing.

Reference: The Hindu

PMF IAS Pathfinder for Mains – Question 749

Q. As India aspires to emerge as a leading global bioeconomy powerhouse by 2035, the need for a robust biotechnology ecosystem has never been more critical. Critically evaluate India’s bioeconomy landscape, identify key challenges, and suggest strategic interventions to unlock its full potential. (250 Words) (15 Marks)

Approach

Introduction: Write a brief introduction about India’s bioeconomy.
Body: Write about India’s bioeconomy landscape, identify key challenges, and suggest strategic interventions to unlock its full potential.
Conclusion: Emphasis on innovation-driven and sustainable bioeconomy reforms to ensure technological self-reliance, health security, green growth, and inclusive economic development.